Target intelligence / Profile preview

Primary tumor cancer cells (null)

Target
null
Molecular classification
Other
01

Overview

Primary tumor cancer cells are the original malignant epithelial or mesenchymal-derived neoplastic cell populations that initiate uncontrolled growth within an organ. These heterogeneous populations exhibit diverse genetic and phenotypic profiles that influence their ability to proliferate, invade surrounding tissue, evade programmed cell death, interact with stromal components including blood vessels and immune system elements, and ultimately disseminate through lymphatic or hematogenous routes causing metastases. Molecular studies reveal distinct transcriptional signatures associated with metastatic competence involving processes like epithelial-mesenchymal transition (EMT), altered adhesion molecules, chemotaxis factors, KRAS signaling pathways among others. The complexity within these cellular populations poses significant challenges for effective targeted therapy since subclones may differ markedly in drug sensitivity. Understanding their biology through genomic profiling enables personalized treatment approaches aiming both at controlling local disease burden and preventing distant spread.

Other names
Original tumor cellsprimary neoplastic cellsinitial malignant cell population
02

Mechanism of action

Drugs act by: Inhibiting cell division/proliferation; Inducing apoptosis or cell death pathways; Blocking signaling pathways critical for survival/growth (e.g., KRAS signaling, EGFR pathway); Enhancing immune-mediated killing by overcoming immune evasion mechanisms such as HLA gene methylation.

03

Biological functions

Cell proliferationTumor growthMetastatic potentialEvasion of apoptosisInteraction with microenvironment including immune evasion and angiogenesis
04

Disease associations

Cancer initiation and progressionSource of metastatic disease
05

Safety considerations

Intratumoral heterogeneity leading to drug resistance and relapseToxicity from systemic therapies targeting rapidly dividing normal tissues alongside tumorsImmune-related adverse events from immunotherapies aimed at enhancing anti-tumor immunityDifficulty eradicating metastatic seeds originating from these primary tumors due to their diverse properties and microenvironmental interactions
06

Interacting drugs

Various chemotherapeutic agents targeting proliferating cancer cells (e.g., platinum compounds, taxanes)

2 more in the full profile.

07

Biomarkers

Genetic mutations/signatures associated with metastasis potential (e.g., KRAS mutations)Expression levels of receptors or ligands involved in proliferation or metastasisImmune markers such as HLA-A expression affecting immune infiltrationMolecular profiling tests analyze DNA/RNA/protein from these primary tumors to guide therapy selection

Beyond the preview

Go deeper on Primary tumor cancer cells (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primary tumor cancer cells (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call